Clinical trial
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy
NCT01638000 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 12, 2012
- Completion date
- April 24, 2013
- Enrollment
- 1,887 (actual)
- Sites
- 217
Conditions
As the registry lists them; a condition with its own page is linked.